药物调节自噬治疗阿尔茨海默病

Medications regulate autophagy for treatment of Alzheimer’s disease

阿尔茨海默病(Alzheimer’s disease,AD)是以认知功能障碍为临床表现的疾病。过去虽然对AD发病机制研究取得了显著进展,但阻断AD病情发展的有效治疗方法并不令人满意。自噬(autophagy)异常被认为参与AD发病机制,自噬的调节可能成为AD治疗新策略。经mTOR依赖性和非依赖性(Bcl-2/Beclin-1、GSK-3β和p-AKT等)途径调节自噬的药物显示出很好的缓解AD症状作用。此外,一些从植物中提取出的化合物也被报道可经多途径、多靶标调节自噬阻止AD进展。本文对近期有关药物包括植物提取药物调节自噬治疗AD的研究进展作一综述,为临床治疗AD提供新的理论基础。

Alzheimer’s disease(AD)is characterized clinically as irreversible cognitive dysfunction.Although a significant progress has been made in the study of AD pathogenesis,the effective measures to block AD progress have not been satisfactory.Abnormal autophagy is thought to be involved in the pathogenesis of AD,and regula‐tion of autophagy may become a new strategy for AD treatment.Some medicines,which regulate autophagy by mTOR-dependent and independent(Bcl-2/Beclin-1,GSK-3β,and p-AKT)pathways,have shown excellent effects in alleviating AD symptoms.In addition,certain compounds extracted from plants have also been reported to regulate autophagy and prevent AD progression through multiple pathways and multiple targets.This article reviews the recent advances in the regulation of autophagy and AD treatment.It provides a new theoretical basis for clinical treatment of AD.